

**EXTREMITY**<sup>®</sup>  
MEDICAL

Real change *starts* here™

# NeoMTX™

Viable Bone Matrix

An Allograft with the  
**Critical Components  
of Autograft**

The Power of Biology, Reimagined.



[www.ExtremityMedical.com](http://www.ExtremityMedical.com)

# Rigorous Organ Donor Standards and Advanced Tissue Processing

Strict Donor Screening & Tissue Recovery	Tissue Processing	Packaging & Cryopreservation
≤ 8 hrs	≤ 72 hrs	≤ 82 hrs

All donors are screened according to FDA requirements for HCT/Ps, AATB requirements for tissue, and OPTN requirements for organs.

## Osteoconductive

The physical, three-dimension **scaffold** surface for bone growth.


Cancellous bone, the trabecular matrix, is the optimal microenvironment for bone cells to attach, proliferate and remodel.<sup>2</sup>

Cancellous bone healing is less affected by the inflammatory response.<sup>3</sup>

Cancellous bone enables re-vascularization faster than cortical bone.<sup>4</sup>

**An allograft with the critical component of autograft, NeoMTX provides mineralized cancellous bone as the scaffold.**

NeoMTX is approximately  
**80%**  
cancellous bone,  
the optimal  
scaffold.



## Osteogenic

The transformation of **cells** into bone tissue.

The mineralized component of an autograft is critically important for its osteogenic capacity.<sup>1</sup> The osteogenic capacity of a bone graft declines with age:<sup>1</sup> bone mass typically peaks prior to 50 years of age.<sup>5</sup>

Donor Source	Cell Viability	Cell Count
Organ Donor	≥ 70% Post Thaw	~ 2,000,000 vertebral bone adherent cells (vBA)/cc (verified post thaw)
Age Restricted ≤ 55 yrs		
Median Age: ~ 35 yrs		

## Osteoinductive

The ability of chemical **signals** to induce a biologic response.

**NeoMTX contains physiologic levels of naturally occurring growth factors.**

Growth Factor	Category	Function
BMP-2	Osteogenic	Bone development <sup>6</sup>
BMP-4		Most potent Osteoinductive protein <sup>7</sup>
BMP-7		Regulates bone formation and fracture repair
VEGF	Angiogenic	Vascularity and maintenance of normal bone remodeling and ossification in bone repair <sup>8</sup>
PDGF-BB	Proliferation	Most biologically effective PDFG subtype with mitogenic activity in Osteoblasts <sup>9</sup>
FGF-1		
FGF-2		Accelerates fracture healing and treat Osteoporosis <sup>9</sup>
BMP-9	Signalling	Most potent BMP for MSC osteogenic signaling <sup>7</sup>
Osteopontin	Bone Density, Recruitment, Differentiation	Skews MSCs to bone formation; maintains bone mass <sup>5</sup>
Osteoactivin		Aids in recruitment of MSCs to fracture site; polarization of MSCs to macrophages to M2 to reduce inflammation

Validated process to confirm bone formation and remodeling genes, verified by RNA sequencing.



# Advanced Processing Optimal Handling

## No added demineralized bone particulates

- Approximate 5 Minute Thaw Time
- No Decanting
- USP <71> Sterility Tested
- Highly formable to pack in limited space voids
- Maintains graft integrity after significant handling or lavage

Part #	Description	Size
145-80025	Neo MTX Viable Bone Matrix	2.5 cc
145-80050	Neo MTX Viable Bone Matrix	5.0 cc
145-80100	Neo MTX Viable Bone Matrix	10 cc
145-80150	Neo MTX Viable Bone Matrix	15 cc



## Footnotes

1. A WNT protein therapeutic improves the bone-forming capacity of autografts from aged animals. Tao Chen, et al. Sci Rep. 2018; Jan 8;8:119
2. Oftadeh R, et al. Biomechanics and Mechanobiology of Trabecular Bone: A Review. Journal of Biomechanical Engineering, 2015; 137 3.
3. Sandberg, O. et al., Inter-trabecular bone formation: a specific mechanism for healing of cancellous bone, Acta Orthop, 2015.
4. Kumagai, K. et al. 2008. J. Ortho. Res. / Liu, R. et al. 2011. BMC Musculoskelet. Disord. / Neagu, T. et al. 2016. Rom. J. Morphol. Embryol. Rabie, A. B., et al. 1996. Int. J. Oral Maxillofac. Surg. / Colnot, C. 2009. J. Bone Miner. Res. / Suh, K.T. et al. 2012. J. Magn. Reson. Imaging / Siclari, V.A. et al. 2013. Bone 53, 575-586
5. Bone Biology. International Osteoporosis Foundation. <https://www.osteoporosis.foundation/health-professionals/about-osteoporosis/bone-biology>
6. Halloran D. J Dev Bio. 2020; 8(3): 19
7. Wei Z. Biol Chem. 2014, 289 (45): 31150-31159
8. Hu K. Bone. 2016; 91: 30-38
9. Sun J. Braz J Med Biol Res. 2021; 54(2): e9944
10. i J. Med Sci Monit. 2020; 26: e919159-1

## Extremity Medical

973.588.8980

ExtremityMedical.com

customerservice@ExtremityMedical.com

300 Interpace Parkway, Building A, Floor 2 Parsippany, NJ 07054

## Ossium Health

5742 W. 74th Street | Indianapolis, IN 46278

Distributed by

**EXTREMITY**  
MEDICAL

Real change *starts* here™

Processed by



**OSSIUM HEALTH**®

NeoMTX™ and Extremity Medical® are trademarks of Extremity Medical, LLC.

© 2024 Extremity Medical, LLC. All Rights Reserved.

MKT-174-00001 REV B 02/2025